# Genetic risk score-informed re-evaluation of spirometry quality control to maximise power in epidemiological studies of lung function

Jing Chen\*\*, Nick Shrine\*, Abril G Izquierdo\*, Anna Guyatt\*, Henry Völzke\*<br>Hall<sup>4</sup>, Frank Dudbridge<sup>1</sup>, SpiroMeta Consortium, CHARGE Consortium, Lou<br>Tobin<sup>1,5</sup>, Catherine John<sup>\*1,5</sup><br><sup>1</sup>Department of Population Health Scien , Stephanie London"<br>iise V Wain<sup>1,5</sup>, Martii<br>ster, UK<br>swald, Germany<br>ss, National Institute<br>k, NC, USA  $\int$ <br>  $\int$ <br>

 $1$ Department of Population Health Sciences, University of Leicester, Leicester, UK

2

Hall"<br>Tobi<br><sup>1</sup>Dep<br><sup>2</sup>lnsti<br><sup>3</sup>Epic<br>Heal'<br><sup>4</sup>Divi , Frank Dudbridge<sup>+</sup><br>n<sup>1,5</sup>, Catherine Johr<br>artment of Populai<br>itute for Communit<br>demiology Branch,<br>th, Department of<br>sion of Respiratory , SpiroMeta Consortium, CHARGE Consortium, Louise V Wain<sup>475</sup>, Martin D<br>1<sup>\*1,5</sup><br>tion Health Sciences, University of Leicester, Leicester, UK<br>ty Medicine, University Medicine Greifswald, Greifswald, Germany<br>National Institu Tobin<sup>4,5</sup>, Catherine John\*<sup>1,5</sup><br><sup>1</sup>Department of Population<br><sup>2</sup>Institute for Community M<br><sup>3</sup>Epidemiology Branch, Nati<br>Health, Department of Heal<br><sup>4</sup>Division of Respiratory Me<br>Nottingham, Nottingham, U Institute for Community Medicine, University Medicine Greifswald, Greifswald, G<br>Epidemiology Branch, National Institute of Environmental Health Sciences, Natio<br>Health, Department of Health and Human Services, Research Tria <sup>3</sup>Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of

 $4$ Division of Respiratory Medicine and NIHR Nottingham Biomedical Research Centre, University of

Institute for Community Medicine, Material, Medicine, Temetricine, Temetricine, Temetricine, Temetricia, Bepar<br>Institute for Medicine and NIHR Nottingham Biomedical Research Centre, University Medicine and NIHR Nottingham realth, Department of Health and Human Services, Research Triangle Park, NC, USA<br>Division of Respiratory Medicine and NIHR Nottingham Biomedical Research Centre, University of<br>Joitingham, Nottingham, UK<br>National Institute 4Division of Respiratory Medicine and NIHR Nottingham Biomedical Research Centre<br>Nottingham, Nottingham, UK<br><sup>5</sup>National Institute for Health Research, Leicester Respiratory Biomedical Research Co<br>of Leicester, Leicester, U Division of Respiratory Medicine and NIHR Nottingham Biomedical Research Centre, University of Leicester, Leicester, UK<br>National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, University o <sup>5</sup>National Institute for Health I<br>of Leicester, Leicester, UK<br>\*Joint corresponding authors:<br>John)<br>**Abstract**<br>Background and aim <sup>5</sup>National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, University

Mational Institute for Alector Mathematical Institute for Heicester, Leicester, Leicester, Leicester, UK<br>1901 National Institute for Health Research, Leicester Research Respiratory Biomedical Research Centre, 1991<br>1991 Nac of Leicester, Leicester, Lei<br>\*Joint corresponding authition<br>John)<br>Abstract<br>Background and aim<br>Epidemiological studies of

# Abstract

#### Background and aim

 $\begin{array}{l} \text{John)} \\ \text{Abstract} \end{array}$ <br>Background and aim<br>Epidemiological studies of lung function may discard one-third to one-half of participants due<br>spirometry measures deemed "low quality" using criteria adapted from clinical p Abs<br>Backg<br>Epider<br>spiron<br>to derepider Epidemiological studies of lung function may alter the lung for lung function particle. We aimed<br>to define new spirometry quality control (QC) criteria that optimise the signal-to-noise ratio in<br>epidemiological studies of

#### Material and methods

spirometry measures deemed with quality intitial and provide the signal-to-noise ratio in<br>the define new spirometry quality control (QC) criteria that optimise the signal-to-noise ratio in<br>epidemiological studies of lung f to define the spirometry quality control (QC) control that spirits that signal-to-noise ratio in<br>epidemiological studies of lung function.<br>We proposed a genetic risk score (GRS) informed strategy to categorize spirometer b Material and methods<br>We proposed a genetic risk score (GRS) is<br>to quality criteria. We constructed three<br>volume in 1 second (FEV<sub>1</sub>), forced vital<br>individuals from non-UK Biobank cohorts<br>In the UK Biobank, we applied a ste to quality criteria. We constructed three GRSs comprised of SNPs associated with forced expiratory<br>volume in 1 second (FEV<sub>1</sub>), forced vital capacity (FVC) and the ratio of FEV<sub>1</sub> to FVC (FEV<sub>1</sub>/FVC) in<br>individuals from n volume in 1 second (FEV<sub>1</sub>), forced vital capacity (FVC) and the ratio of FEV<sub>1</sub> to FVC (FEV<sub>1</sub>/FVC) in<br>individuals from non-UK Biobank cohorts included in prior genome-wide association studies (GWAS).<br>In the UK Biobank, volume in 1 second (FEV1), the ratio of prior, (FCP) and the ratio of FEV1 to FCP1), individuals from non-UK Biobank cohorts included in prior genome-wide association studies (GWAS).<br>In the UK Biobank, we applied a step-wi In the UK Biobank, we applied a step-wise testing of the GRS association across groups of spirometry<br>blows stratified by acceptability flags to rank the blow quality. To reassess the QC criteria, we<br>compared the genetic as In the UK Biobana strained by acceptability flags to rank the blow quality. To reassess the QC criteria, we compared the genetic association results between analyses including different acceptability flags and applying dif blows strategies and applying different repeatability thresholds for spirometry measurements to determine the trade-off between sample size and measurement error.<br>Results<br>We found that including blows previously excluded f

#### Results

Empared the general acceptability thresholds for spirometry measurements to determine the trade-off between sample size and measurement error.<br> **Results**<br>
We found that including blows previously excluded for cough, hesita and applying different repeatability interesting for spiritually interest in the determine the statistical power<br>Results<br>We found that including blows previously excluded for cough, hesitation, excessive time to peak<br>flow, Results<br>We found that including blows previously excluded fo<br>flow, or inadequate terminal plateau, and applying<br>maximise the statistical power for GWAS and retain a<br>approach allowed the inclusion of 29% more partic<br>guideli We flow, or inadequate terminal plateau, and applying a repeatability threshold of 250ml, would<br>maximise the statistical power for GWAS and retain acceptable precision in the UK Biobank. This<br>approach allowed the inclusion flow, or industry and application, and applying a repeatable precision in the UK Biobank. This<br>maximise the statistical power for GWAS and retain acceptable precision in the UK Biobank. This<br>approach allowed the inclusion manimum and retail power for CMAS and retain acceptable precision in the UK Biobank that<br>approach allowed the inclusion of 29% more participants compared to the strictest ATS/ERS<br>guidelines.<br>Conclusion<br>Our findings demonst

#### Conclusion

guidelines.<br>
Conclusion<br>
Our findings demonstrate the utility of GRS-informed QC to maximise the power of epidemiological<br>
studies for lung function traits.<br>
1<br>
TE: This preprint reports new research that has not been cert Conclusion<br>Conclusion<br>Our finding<br>studies for<br>TE: This prepr Our findings for lung function traits.<br>
This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practic<br>
This preprint reports new research that has not been c

# **Introduction**

Including chronic obstructive pulmonary disease (COPD), but also predicts mortality in the general<br>population[1]. Genome-wide association studies (GWAS) have proven to be an effective tool for<br>identifying genetic variants population[1]. Genome-wide association studies (GWAS) have proven to be an effective tool for<br>identifying genetic variants that are associated with complex diseases and traits, providing valuable<br>insights into disease bio population is a trait of elastic variants that are associated with complex diseases and traits, providing valuable<br>insights into disease biology and informing development of diagnostic tools and potential<br>treatments[2]. Fo insights into disease biology and informing development of diagnostic tools and potential<br>treatments[2]. For lung function, the most recent GWAS identified associated genetic variants<br>explaining 33% of the heritability of

insights into disease biology and informally development of diagnostic tools and potential<br>treatments[2]. For lung function, the most recent GWAS identified associated genetic variants<br>explaining 33% of the heritability o explaining 33% of the heritability of FEV<sub>1</sub>/FVC (less for FEV<sub>1</sub> and FVC)[3], indicating that additional<br>associations could be found in more powerful studies.<br>However, GWAS of lung function may discard one-third to one-ha explaining 33% of the heritability of FEV1/FVC (CEP1/FUC) and FEV1/FUC) massing that analysing<br>associations could be found in more powerful studies.<br>However, GWAS of lung function may discard one-third to one-half of parti However, GWAS of lung function may discard one-thirm<br>measures deemed "low quality", substantially limiti<br>measures the flow and volume of air over time, typi<br>vigorous, complete exhalation following maximal in<br>parameters. Sp However, CHME of low quality", substantially limiting the potential sample size[4]. Spirometry<br>measures the flow and volume of air over time, typically in a forced expiratory manoeuvre, i.e. a<br>vigorous, complete exhalation measures the flow and volume of air over time, typically in a forced expiratory manoeuvre, i.e. a vigorous, complete exhalation following maximal inhalation. **Figure 1** illustrates key spirometric parameters. Spirometry is measures the flow and visitation following maximal inhalation. Figure 1 illustrates key spirometric<br>parameters. Spirometry is effort and technique-dependent, and thorough quality control (QC) is<br>considered essential to ens vigorous, complete exhalation following maximal immatation. Figure 1 mastrates key spirometric<br>parameters. Spirometry is effort and technique-dependent, and thorough quality control (QC) is<br>considered essential to ensure m parameters. Spirometry is there and technique dependent, and thorough quality centre ( $\chi$ ) is<br>considered essential to ensure measurements are unaffected by inadequate technique or artefacts<br>(such as a cough). However, it (such as a cough). However, it has been suggested that "Pulmonary function standards are not static.<br>They should be questioned. There is always room for improvement in any set of pulmonary function<br>standards"[5, 6]. Moreov They should be questioned. There is always room for improvement in any set of pulmonary function<br>standards"[5, 6]. Moreover, QC for epidemiological studies may not require the same level of<br>stringency as clinical practice, standards"[5, 6]. Moreover, QC for epidemiological studies may not require the same level of<br>stringency as clinical practice, where results are used for diagnosis and management of individual<br>patients. Hankinson *et al.* h stringency as clinical practice, where results are used for diagnosis and management of individual<br>patients. Hankinson *et al.* have previously suggested visual inspection of blow curves by human<br>reviewers in addition to c patients. Hankinson *et al.* have previously suggested visual inspection of blow curves by human<br>reviewers in addition to computer assessment to avoid unnecessary rejection of valid data[7]. While<br>this approach could enhan

patients. Hankinson et al. have previously suggested visual inspection of blow curves by human<br>reviewers in addition to computer assessment to avoid unnecessary rejection of valid data[7]. While<br>this approach could enhance reviewers in addition to computer accordance to direct anti-computer projection of the subsection of the subject to bias.<br>
Genetic information can predict individual continuous traits such as lung function by tallying the<br> the information could be subject to bias.<br>
Genetic information can predict individual continuous traits such as lung function by tallying the<br>
number of risk alleles for each individual to give a genetic risk score (GRS) ( Senetic information can predict ind<br>number of risk alleles for each incomplygenic risk score, PRS, or polyge<br>millions of genetic variants and are<br>the trait of interest[8]. By checking con genetics and the actual measure number of risk alleles for each individual to give a genetic risk score (GRS) (sometimes called<br>polygenic risk score, PRS, or polygenic score, PGS, **Figure 2**) [8]. These may include hundreds to<br>millions of genetic variant polygenic risk score, PRS, or polygenic score, PGS, Figure 2) [8]. These may include hundreds to millions of genetic variants and are typically weighted by the size of association of each allele with the trait of interest[ polygenic risk score, PRS, or polygenic score, PGS, Figure 2) [8]. These may include hundreds to<br>millions of genetic variants and are typically weighted by the size of association of each allele with<br>the trait of interest[ the trait of interest[8]. By checking concordance between the predicted lung function values based<br>on genetics and the actual measured lung function traits, we can reassess the value of spirometer<br>blows that were previousl on genetics and the actual measured lung function traits, we can reassess the value of spirometer<br>blows that were previously deemed as "low quality". In this study, we aimed to establish new<br>spirometry QC criteria informed on generate and the actual measured lung function traits, the function of shows that were previously deemed as "low quality". In this study, we aimed to establish new spirometry QC criteria informed by GRS to optimise the below that were previously deemed as "low quality". In this study, we annual to establish new spirometry QC criteria informed by GRS to optimise the signal-to-noise ratio in epidemiological studies.<br> **Methods**<br>
We undertoo

# **Methods**

### Spirometry quality control

studies.<br>Spirometry quality control<br>We undertook analyses in the UK Biobank European population [9]. In UK Biobank, each individual<br>We undertook analyses in the UK Biobank European population [9]. In UK Biobank, each indiv Meth<br>Meth<br>Spiron<br><sub>Was aske</sub><br>6800). T Was asked to perform up to three blows on a Vitalograph spirometer (Vitalograph Pneumotrac<br>6800). These blows were used to derive measures of lung function, including the forced expiratory<br>volume in 1 second (FEV<sub>1</sub>), for 6800). These blows were used to derive measures of lung function, including the forced expirat<br>volume in 1 second (FEV<sub>1</sub>), forced vital capacity (FVC) and the ratio of FEV<sub>1</sub> to FVC (FEV<sub>1</sub>/FVC), fi<br>spirogram (volume-tim blow in 1 second (FEV<sub>1</sub>), forced vital capacity (FVC) and the ratio of FEV<sub>1</sub> to FVC (FEV<sub>1</sub>/FVC), from spirogram (volume-time curve) recorded by the Vitalograph software.<br>A blow received an automated error code from the

volume time curve) recorded by the Vitalograph software.<br>
A blow received an automated error code from the spirometry software if: (1) there was hesitation<br>
(excessive extrapolated volume[10] at the start of the blow, code A blow received an automated error code from the spirometry softw<br>(excessive extrapolated volume[10] at the start of the blow, coded "<br>2 (excessive extrapolated volume[10] at the start of the blow, coded "START"); (2) the time to peak<br>2 (extrapolated value)  $\frac{1}{2}$  at the start of the blow,  $\frac{1}{2}$  ( $\frac{1}{2}$ ) at time to peak

there was not an adequate plateau at the end of the blow ("END") (see **Table 1** for additional detail).<br>It was also possible for the spirometer operator to explicitly reject the blow ("REJECT"). In previous<br>GWAS of lung fu It was also possible for the spirometer operator to explicitly reject the blow ("REJECT"). In previous<br>GWAS of lung function, blows were deemed unacceptable and excluded from analysis if they had<br>any of the above error cod GWAS of lung function, blows were deemed unacceptable and excluded from analysis if they had<br>any of the above error codes[4]. Additionally, as in previous GWAS[3, 4], we checked each blow for<br>inappropriate negative values any of the above error codes[4]. Additionally, as in previous GWAS[3, 4], we checked each blow for<br>inappropriate negative values which indicate a problem with the blow (for any of: forced expiratory<br>flow at 25% of FVC; fo inappropriate negative values which indicate a problem with the blow (for any of: forced expiratory<br>flow at 25% of FVC; forced expiratory flow at 75% of FVC; average forced expiratory flow between<br>25% and 75% of the FVC; Find 25% of FVC; forced expiratory flow at 75% of FVC; average forced expiratory flow between<br>25% and 75% of the FVC; peak flow; extrapolated volume; volume at forced expiratory time) (coded<br>"NEGATIVE"), the start of the 25% and 75% of the FVC; peak flow; extrapolated volume; volume at forced expiratory time) (coded "NEGATIVE"), the start of the blow underwent a further check for hesitation ("START2"), and consistency (<5% difference) was "NEGATIVE"), the start of the blow underwent a further check for hesitation ("START2"), and<br>consistency (<5% difference) was checked between the FEV<sub>1</sub> and FVC output from the spirometer<br>and that rederived from the spirog consistency (<5% difference) was checked between the FEV<sub>1</sub> and FVC output from the spirometer<br>and that rederived from the spirogram ("CONSISTENCY"). In this study, we identified blows that<br>would previously have failed QC consistency (CH) and that rederived from the spirogram ("CONSISTENCY"). In this study, we identified blows that<br>would previously have failed QC due to any of the above error codes or additional QC steps, and<br>labelled these and that rederived from the spirogram ("CONSISTENCY"), the studies and the distribution<br>would previously have failed QC due to any of the above error codes or additional QC steps, and<br>labelled these with corresponding "acc

### Testing the association between GRSs and lung function traits derived from spirometer blow measurements

Habelled these with corresponding "acceptability flags" (Table 1).<br>Testing the association between GRSs and lung function traits derived from<br>spirometer blow measurements<br>We calculated the GRSs for European-ancestry indivi labelled these with corresponding "acceptability flags" (**Table 1**).<br>Testing the association between GRSs and lung fu<br>spirometer blow measurements<br>We calculated the GRSs for European-ancestry individuals in L<br>weights train weights trained from Shrine *et al.* [3] (**Supplementary Methods**). In the UK Biobank European population, we then conducted iterative testing of the GRS association within groups of spirometry blows stratified by acceptab weights trained from Shime et al. [3] (Supplementary Methods). In the OK Biobank European<br>population, we then conducted iterative testing of the GRS association within groups of spirometry<br>blows stratified by acceptability population, we then conducted iterative statified by acceptability flags, to identify and rank the flags most likely to cause failure of spirometry blow quality (Figure 3). For each lung function trait, we first stratified blow quality (Figure 3). For each lung function trait, we first stratified all the blows by acceptability flag (Figure 3, step I, Supplementary Methods). Where lung function measures within a stratum showed no significant spirometry blow quality (Figure 3). For each lung function trait, we first stratified all the blows by acceptability flag (Figure 3, step I, Supplementary Methods). Where lung function measures within a stratum showed no s a stratum showed no significant association with the GRS (P>0.05), we considered that the corresponding acceptability flag to indicate unacceptable blow quality and thus a reason for exclusion. For the remaining blows, we corresponding acceptability flag to indicate unacceptable blow quality and thus a reason for exclusion. For the remaining blows, we applied an iterative selection process to identify the acceptability flags that were most exclusion. For the remaining blows, we applied an iterative selection process to identify the<br>acceptability flags that were most likely to cause failure of spirometry blow quality as shown in<br>Figure 3 (Step II). Based on t exceptability flags that were most likely to cause failure of spirometry blow quality as shown in<br>Figure 3 (Step II). Based on the outcome of this, we ranked the remaining acceptability flags<br>according to their impact on t

### Re-evaluating spirometry QC criteria for association study

Figure 3 (Step II). Based on the outcome of this, we ranked the remaining acceptability flags according to their impact on the spirometer blows in our new approach (see Results for details).<br>Re-evaluating spirometry QC cr Figure 3 (Step II). Based on the outcome of this, we ranked the remaining acceptability riags<br>according to their impact on the spirometer blows in our new approach (see Results for details).<br>Re-evaluating spirometry QC cri Re-evaluating spirometry QC criteria for association study<br>Based on the grouping of blows above, we then aimed to identify which acceptability<br>repeatability criteria would maximise the association of the lung function meas Frepeatability criteria would maximise the association of the lung function measures with GRS as<br>measured by the level of statistical significance (Z-score for the association) (Figure 3, Step III). We<br>varied our acceptabi measured by the level of statistical significance (Z-score for the association) (**Figure 3, Step III**). We varied our acceptability criteria by including blows with acceptability flags in order of the ranking generated in measured by the level of statistical significance (Z-score for the association) (Figure 3, Step III). We<br>varied our acceptability criteria by including blows with acceptability flags in order of the ranking<br>generated in th varied in the previous step, in addition to blows previously considered acceptable. We also<br>varied our repeatability threshold (from 150ml to 400ml in 50ml increments). Repeatability was<br>based on the difference from any ot

generate in the presention of the previously considered in the previously varied our repeatability threshold (from 150ml to 400ml in 50ml increments). Repeatability was based on the difference from any other blow, even if based on the difference from any other blow, even if that blow was not accepted. Using these different criteria, we tested the association with the GRS.<br>To ensure that effect size estimates retained acceptable precision w different criteria, we tested the association with the GRS.<br>To ensure that effect size estimates retained acceptable precision whilst maximising statistical<br>significance, we then tested genetic associations with the sentin To ensure that effect size estimates retained acceptal<br>significance, we then tested genetic associations with the<br>lung function[3], using the different acceptability criter<br>above, and examined the effect sizes and P-values significance, we then tested genetic associations with the sentinel SNPs known to be associated with<br>lung function[3], using the different acceptability criteria and repeatability thresholds described<br>above, and examined showe, and examined the effect sizes and P-values for sentinels of lung function signals using these<br>above, and examined the effect sizes and P-values for sentinels of lung function signals using these<br>different QC criter above, and examined the effect sizes and P-values for sentinels of lung function signals using these different QC criteria. All lung function traits were untransformed, adjusting for age, age<sup>2</sup>, height, smoking status, a different QC criteria. All lung function traits were untransformed, adjusting for age, age<sup>2</sup>, height,<br>smoking status, and relatedness (mixed models in BOLT-LMM[11]).<br>3 different QC criteria. All lung function traits were untransformed, adjusting for age, age<sup>2</sup><br>smoking status, and relatedness (mixed models in BOLT-LMM[11]).<br>3 , here  $\frac{1}{2}$  $s_{\rm obs}$  status, and relations (mixed models in BOLT-LMM $_{\rm 1--}$ ).

#### Assessing the credibility of GWAS findings

conducted a GWAS in the UK Biobank European population as an example to compare GWAS<br>findings with those found using the previous QC criteria. Credibility of newly identified signals was<br>assessed using a Bayesian framewor findings with those found using the previous QC criteria. Credibility of newly identified signals was<br>assessed using a Bayesian framework previously described by Okbay *et al* [12]and Turley *et al* [13]<br>(**Supplementary m** 

### Results

findings with these found using the previously described by Okbay *et al* [12] and Turley *et al* [13]<br>assessed using a Bayesian framework previously described by Okbay *et al* [12] and Turley *et al* [13]<br>**ReSUItS**<br>In UK **Supplementary methods**).<br> **ReSUItS**<br>
In UK Biobank, 445,541 individuals had at least two measures of FEV<sub>1</sub> and FVC, along with complete<br>
information for age, sex, standing height and derived smoking status (smoking stat (Supplementary methods).<br>
Results<br>
In UK Biobank, 445,541 indi<br>
information for age, sex, st<br>
Shrine *et al.* 2019[4]. Of th<br>
measurements (UK Bioban<br>
measurements (UK Bioban Information for age, sex, standing height and derived smoking status (smoking status derived by Shrine *et al.* 2019[4]. Of these individuals, 406,474 were assigned as European ancestry using k-<br>means clustering and ADMIX Shrine *et al.* 2019[4]. Of these individuals, 406,474 were assigned as European ancestry using k-<br>means clustering and ADMIXTURE v1.3.0[14] as described in Shrine *et al*[4]. We used FEV<sub>1</sub> and FVC<br>measurements (UK Bioba Shrine et al. 2019[4]. Of these individuals, 400,474 were assigned as European ancestry using K-<br>means clustering and ADMIXTURE v1.3.0[14] as described in Shrine *et al*[4]. We used FEV<sub>1</sub> and FVC<br>measurements (UK Biobank means clustering and ADMIXTORE V1.3.0[14] as described in Shiffle et al[4]. We used TEV1 and TVC<br>measurements (UK Biobank Field ID 20031) and the Vitalograph spirometer blow quality metrics (UK<br>Biobank Field ID 20031).<br>Eva

#### Evaluating spirometer blows quality with different acceptability flags

measurements (UK Biobank Field ID 20031) and the Vitalograph spirometer blow quality metrics (UK<br>Biobank Field ID 20031).<br>Evaluating spirometer blows quality with different acceptability flags<br>Using the previous, more str Biobank Field ID 20031).<br>Evaluating spirometer blows quality with different acceptability flags<br>Using the previous, more stringent approach to spirometry QC, we identified 713,885 spirometer<br>blows as "accepted" for 354,74 Evaluating spirome<br>Using the previous, mor<br>blows as "accepted" for<br>"accepted" blows for the<br>95% CI [0.243, 0.249], P<<br>From the association of

blows as "accepted" for 354,746 European individuals. The best measures of FEV<sub>1</sub>/FVC derived from<br>"accepted" blows for these individuals were strongly associated with the GRS ( $\beta_{SD\_change\_of\_GRS}$ =0.246,<br>95% CI [0.243, 0.249], Fracepted" blows for these individuals were strongly associated with the GRS ( $\beta_{SD\_change_of_GRS}$ =0.246,<br>95% CI [0.243, 0.249], P<1.00E-300) (**Figure 4a**).<br>From the association of GRS with the FEV<sub>1</sub>/FVC derived from blows in ea 95% CI [0.243, 0.249], P<1.00E-300) (Figure 4a).<br>
From the association of GRS with the FEV<sub>1</sub>/FVC derived from blows in each of our acceptability flag<br>
strata, blows with acceptability flags "CONSISTENCY", "NEGATIVE" or " From the association of GRS with the FEV<sub>1</sub>/FVC<br>strata, blows with acceptability flags "CONSISTE<br>with the GRS (Figure 4a), indicating that these a<br>blow quality ( $\beta_{SD\_change\_of\_GRS}$ =-0.022, 95% CI [-0.1<br>the remaining acceptabil From the associated with acceptability flags "CONSISTENCY", "NEGATIVE" or "REJECT" were not associated<br>with the GRS (Figure 4a), indicating that these acceptability flags represent unacceptable spirometry<br>blow quality ( $\$ strata, and the GRS (Figure 4a), indicating that these acceptability flags represent unacceptable spirometry<br>blow quality ( $\beta_{SD\_change\_of\_GRS} = -0.022$ , 95% CI [-0.049, 0.006], p=0.1292, Figure 4c, Group 3). To rank<br>the remainin blow quality ( $\beta_{SD\_change\_of\_GRS} = -0.022$ , 95% CI [-0.049, 0.006], p=0.1292, **Figure 4c, Group 3**). To rank<br>the remaining acceptability flags that cause failure of the spirometry blow quality in descending<br>order of severity, we the remaining acceptability flags that cause failure of the spirometry blow quality in descending<br>order of severity, we conducted an iterative selection process (**Figure 4b**). In the first round of<br>selection (round 1), we the remaining acceptancies, magnitude content cause (Figure 4b). In the first round of selection (round 1), we identified excessive time to peak flow ("EXPFLOW") as the next most likely cause of failure of spirometry quali order of severity, we conducted an iterative selection process (rigure 4b). In the first round or<br>selection (round 1), we identified excessive time to peak flow ("EXPFLOW") as the next most likely<br>cause of failure of spiro cause of failure of spirometry quality. This was based on the observation that additionally removing<br>blows with "EXPFLOW" flag led to an increase in the magnitude of the effect size estimate in the<br>association results in blows with "EXPFLOW" flag led to an increase in the magnitude of the effect size estimate in the association results in all the remaining strata. Similarly, we identified an inadequate terminal plateau ("END", round 2) an blows with the flags excluded in previous steps. For the remaining flags relating to hastociation results in all the remaining strata. Similarly, we identified an inadequate terminal plateau ("END", round 2) and cough ("C ("END", round 2) and cough ("COUGH", round 3) as the next most likely to cause failure of<br>spirometry quality in the subsequent rounds of selection. Collectively, blows from groups<br>"EXPFLOW", "END" and "COUGH" were associa spirometry quality in the subsequent rounds of selection. Collectively, blows from groups<br>
"EXPFLOW", "END" and "COUGH" were associated with GRS but with a smaller effect size than<br>
previously accepted blows ( $\beta_{SD\_change\_of\_GRS$ "EXPFLOW", "END" and "COUGH" were associated with GRS but with a smaller effect size than<br>previously accepted blows ( $\beta_{SD\_change\_of\_GRS}$ =0.149, 95% CI [0.145, 0.153], p<1.00E-300, **Figure 4c,**<br>**Group 2**), after removing blows previously accepted blows ( $\beta_{SD\_change\_of\_GRS}$ =0.149, 95% CI [0.145, 0.153], p<1.00E-300, **Figure 4c,**<br> **Group 2**), after removing blows with the flags excluded in previous steps. For the remaining flags<br>
relating to hesitatio previously accepted blows ( $p_{SD\_change\_of\_GRS} = 0.149$ ,  $p_{S1\_O14} = 0.143$ ,  $p_{S1\_OOL} = 0.06$ , righte 4c, Group 2), after removing blows with the flags excluded in previous steps. For the remaining flags relating to hesitation ( Group 2), after removing blows with the flags excluded in previous steps. For the remaining riags<br>relating to hesitation ("START" and "START2"), the magnitude of the effect size of GRS association in<br>the corresponding str

The corresponding strata ( $\beta_{SD\_change\_of\_GRS}$ =0.262, 95% CI [0.240, 0.284], P=1.14E-118, Figure 4c, Group<br>1) was similar to that from the acceptable blows ( $\beta_{SD\_change\_of\_GRS}$ =0.246, 95% CI [0.243, 0.249],<br>P<1.00E-300, Figure 4c, A the corresponding strata (psp\_change\_of\_GRS=0.262, 95% CI [0.244, 0.264], 1 = 1.14E-118, Figure 4c, Group<br>
1) was similar to that from the acceptable blows (β<sub>SD\_change\_of\_GRS</sub>=0.246, 95% CI [0.243, 0.249],<br>
P<1.00E-300, 1) Was similar to that from the acceptable blows (PSD\_change\_of\_GRS=0.246, 35% Cr [0.243, 0.243],<br>P<1.00E-300, **Figure 4c, Accepted blows**), after removing blows with all the other acceptability flags.<br>For FEV<sub>1</sub> and FVC, For FEV<sub>1</sub> and FVC, we observed similar results to those for FEV<sub>1</sub>/FVC above in ranking the spirometer<br>blow quality but with the "COUGH" flag showing a similar effect size to accepted blows<br>(**Supplementary Figure 1 and S** For FEV1 and FVC and FVC, we based our subsequent analyses on FEV<sub>1</sub>/FVC.<br>
(Supplementary Figure 1 and Supplementary Figure 2). For FVC, "END" had a larger impact than<br>
"EXPFLOW". Since the results suggest acceptability f **Supplementary Figure 1 and Supplementary Figure 2**). For FVC, "END" had a larger impact than "EXPFLOW". Since the results suggest acceptability flags have greater impact on the measurements of FEV1/FVC than FEV1 and FVC, (Supplementary Figure 1 and Supplementary Figure 2). For FVC, END Thad a larger impact than<br>
"EXPFLOW". Since the results suggest acceptability flags have greater impact on the measurements<br>
of FEV1/FVC than FEV1 and FVC, of FEV1/FVC than FEV1 and FVC, we based our subsequent analyses on FEV<sub>1</sub>/FVC.<br>4  $\begin{align} \mathbf{q} \end{align}$ 

### Re-evaluating spirometry QC criteria for association studies

inclusion criteria for spirometry QC. To do this, we included blows with varying acceptability flags<br>with their inclusion ordered according to the findings above, and applied different repeatability<br>thresholds to assess th including inclusion ordered according to the findings above, and applied different repeatability<br>thresholds to assess their impact on the association between GRS and FEV<sub>1</sub>/FVC. We found that<br>including blows previously exc thresholds to assess their impact on the association between GRS and FEV<sub>1</sub>/FVC. We found that<br>including blows previously excluded for cough (COUGH), hesitation (START/START2), excessive time<br>to peak flow (EXPFLOW) or lack including blows previously excluded for cough (COUGH), hesitation (START/START2), excessive time<br>to peak flow (EXPFLOW) or lack of terminal plateau (END) in addition to accepted blows and applying<br>a repeatability threshold to peak flow (EXPFLOW) or lack of terminal plateau (END) in addition to accepted blows and applying<br>a repeatability threshold of 350ml reached the maximum statistical significance in the association<br>between GRS and FEV<sub>1</sub>

to peak flow (EXPTLOM) or lack of 350ml reached the maximum statistical significance in the association<br>between GRS and FEV<sub>1</sub>/FVC. However, as expected, the effect size in the association results<br>attenuated toward zero as between GRS and FEV<sub>1</sub>/FVC. However, as expected, the effect size in the association results<br>attenuated toward zero as QC criteria were successively relaxed (**Table 2**).<br>To balance accuracy of effect size estimation versus between The Tank Ferry Contentation, and Tapperten, the Entertainment Term and Terms can<br>attenuated toward zero as QC criteria were successively relaxed (Table 2).<br>To balance accuracy of effect size estimation versus maxim attenuated toward zero as QC criteria were successively relaxed (Table 2).<br>To balance accuracy of effect size estimation versus maximising statistica<br>genome-wide association studies, we examined the changes in the effect<br>s genome-wide association studies, we examined the changes in the effect sizes and P values of the sentinels of FEV<sub>1</sub>/FVC signals identified by Shrine *et al*[3]. We found that additionally including blows previously exclu gentinels of FEV<sub>1</sub>/FVC signals identified by Shrine *et al*[3]. We found that additionally including blows<br>previously excluded for cough (COUGH), hesitation (START/START2), excessive time to peak flow<br>(EXPFLOW) or lack o sentifiels of FEV1/FVC signals identified by Shrine et al[3]. We found that additionally including blows<br>previously excluded for cough (COUGH), hesitation (START/START2), excessive time to peak flow<br>(EXPFLOW) or lack of te (EXPFLOW) or lack of terminal plateau (END), and applying a repeatability threshold of 250 ml<br>optimized the signal-to-noise ratio in genetic association testing (Figure 5). Based on this finding, we<br>proposed a new spiromet optimized the signal-to-noise ratio in genetic association testing (Figure 5). Based on this finding, we<br>proposed a new spirometry QC strategy for epidemiological studies, which retained 29% more<br>participants using stricte proposed a new spiral-to-noise ratio in genetic association testing (Figure 5). Based on this finding, we<br>proposed a new spirometry QC strategy for epidemiological studies, which retained 29% more<br>participants using stric

### Illustrate the gain in power using newly defined QC criteria

participants using strictest ATS/ERS guidelines and increased the sample size from 275,084 to 356,053 individuals.<br>Illustrate the gain in power using newly defined QC criteria<br>Using the newly defined spirometry QC criteri Barticipants using stricted QC criteria<br>
Using the newly defined spirometry QC criteria, the UK Biobank sample size increased from 320,591<br>
in the most recent GWAS of lung function to 356,053, an 11% gain in sample size, Illustrate the gain<br>Using the newly definithe most recent G<br>statistic (i.e. squared<br>1.29, leading to 15 a<br>on the most signifi in the most recent GWAS of lung function to 356,053, an 11% gain in sample size, and the mean  $\chi^2$ <br>statistic (i.e. squared z scores for SNP and FEV<sub>1</sub>/FVC association) from GWAS increased from 1.27 to<br>1.29, leading to 1 in the most recent GWAS of lung function to 356,053, an 11% gain in sample size, and the mean  $\chi$ <sup>-</sup><br>statistic (i.e. squared z scores for SNP and FEV<sub>1</sub>/FVC association) from GWAS increased from 1.27 to<br>1.29, leading to in the most recent GWAS of lung function to 356,053, an 11% gain in sample size, and the mean  $\chi^2$ <br>statistic (i.e. squared z scores for SNP and FEV<sub>1</sub>/FVC association) from GWAS increased from 1.27 to 1.29, leading to 15 additional sentinel SNPs associated with FEV<sub>1</sub>/FVC (selected 2 Mb regions centred<br>on the most significant variant for all regions containing a variant with  $P < 5 \times 10^{-9}$ , additional<br>compared with ana on the most significant variant for all regions containing a variant with P  $\langle 5 \times 10^{-9} \rangle$  additional<br>compared with analysis of UK Biobank alone using previous QC criteria[3]) (**Supplementary Table 2**).<br>Of these, 7 were on the most significant variant for all regions containing a variant with P <5×10<sup>-</sup>, additional<br>compared with analysis of UK Biobank alone using previous QC criteria[3]) (**Supplementary Table 2**).<br>Of these, 7 were not id compared with analysis of ok biobank alone dsing previous Qc criteria[3]) (supplementary Table 2).<br>Of these, 7 were not identified in the largest GWAS of lung function to date. Examining the nearest<br>genes to the sentinel S These, 7 were noted SNPs, we found two novel genes in addition to 13 genes reported either in the<br>most recent GWAS[3] or the EMBL-EBI GWAS Catalog. One of the novel genes, *FPR3*, encodes the<br>formyl peptide receptor 3, a p genes of the novel genes, *FPR3*, encodes the formyl peptide receptor 3, a paralog of formyl peptide receptor 1. The functional role of *FPR3* is not fully understood. However, it is expressed in a range of immune cells, i most recent GWAS[3] or the EMBL-EBI GWAS catalog. One of the nover genes, FPR3, encodes the<br>formyl peptide receptor 3, a paralog of formyl peptide receptor 1. The functional role of *FPR3* is not<br>fully understood. However, fully understood. However, it is expressed in a range of immune cells, including macrophages and<br>eosinophils, but not neutrophils, so has been hypothesized to play a role in allergic disease[15], and<br>has also been associat eosinophils, but not neutrophils, so has been hypothesized to play a role in allergic disease[15], and<br>has also been associated with asthma and white blood cell counts in GWAS. We also found that<br>enrichment of a previousl

eontinophility in the metallic play of the second that the blood cell counts in GWAS. We also found that enrichment of a previously implicated pathway[3], ESC pluripotency pathway, was strengthened by the newly identified has also been associated with a state and with a state of the newly identified gene *WNT16*.<br>For the newly identified hits, we followed procedures previously described by Okbay *et al.*[12] to<br>calculate the posterior proba the newly identified gene *WNT16*.<br>
For the newly identified hits, we followed procedures previously described by Okbay *et al.*[12] to<br>
calculate the posterior probability of true association, which exceeded 99% for all 1 the newly identified hits, we<br>calculate the posterior probability<br>for any assumption about the prio<br>sentinel SNPs for replication, we<br>(excluding participants from UK Bit<br>the limited statistical power for r For the newly identified hits, we followed procedures previously described by Okbay et  $u_1$ [12] to calculate the posterior probability of true association, which exceeded 99% for all 15 additional loci for any assumption For any assumption about the prior probability of non-null SNPs in the range 1% to 99%. To test the sentinel SNPs for replication, we used meta-analysis results from 42 European ancestry cohorts (excluding participants fr sentinel SNPs for replication, we used meta-analysis results from 42 European ancestry cohorts<br>(excluding participants from UK Biobank) of 249,114 individuals generated by Shrine *et al*[3]. Due to<br>the limited statistical (excluding participants from UK Biobank) of 249,114 individuals generated by Shrine *et al*[3]. Due to the limited statistical power for replication of genome-wide significant association with a smaller sample size, we ap (excluding participants from OK Biobank) of 249,114 individuals generated by Shrine et al[3]. Due to<br>the limited statistical power for replication of genome-wide significant association with a smaller<br>sample size, we appl sample size, we applied methods to assess the replication of the effect size of sentinel SNPs. For the set of 13 newly identified sentinel SNPs for  $FEV_1/FVC$  available in the meta-analysis results, we  $5$ set of 13 newly identified sentinel SNPs for  $FEV_1/FVC$  available in the meta-analysis results, we  $\frac{5}{100}$ set of 13 new letters of 13 new letters in the meta-analysis results, we have  $5$ 

intercept constrained to be zero, after correcting the UK Biobank effect size estimates for winner's<br>curse bias using the method described in Turley *et al*[13]. The regression slope was 0.75 (standard<br>error = 0.1376), be curse bias using the method described in Turley *et al*[13]. The regression slope was 0.75 (standard<br>error = 0.1376), being statistically significantly greater than zero (one-sided P=1.474×10<sup>-4</sup>) but not<br>statistically di curse bias using the method described in Turley et al<sub>[13]</sub>. The regression slope was 0.75 (standard<br>error = 0.1376), being statistically significantly greater than zero (one-sided P=1.474×10<sup>-4</sup>) but not<br>statistically dis

# **Discussion**

error = 0.1376), being statistically significantly greater than zero (one-sided P=1.474×10<sup>-</sup>) but not<br>statistically distinguishable from one (one-sided P=0.0943), suggesting that the newly identified<br>sentinel SNPs were re sentinel SNPs were replicated in independent datasets.<br>
Discussion<br>
QC of spirometric measurements involves a range of metrics and criteria which are designed to<br>
ensure that clinical decision-making is based on accurate a **SHAMP WATER WEREN MARRETS.**<br>
Discussion<br>
QC of spirometric measurements involves a range of<br>
ensure that clinical decision-making is based on<br>
Spirometry is also widely used in epidemiological res<br>
Leading experts in spir Let be premium interest in the spirometric measurements.<br>
Spirometry is also widely used in epidemiological research, including genetic association studies.<br>
Leading experts in spirometry and its QC have previously noted t Spirometry is also widely used in epidemiological research, including genetic association studies.<br>Leading experts in spirometry and its QC have previously noted that, "it is unclear when quality is<br>insufficient for accept Frequision spirometry and its QC have previously noted that, "it is unclear when quality is<br>insufficient for acceptance of results into research studies", and in particular have noted that end-of-<br>test criteria may be appl Leading enpertually and the Calculary previously interds into quality its distinct in sufficient for acceptance of results into research studies", and in particular have noted that end-of-<br>test criteria may be applied too were not identified in the largest GWAS of lung function to date, and two implicated novel genes spirometry curves is not feasible in large-scale association studies, and in this context unnecessary<br>exclusions may impact on power for novel discovery. We propose a new GRS-based method to<br>define a QC strategy which maxi presumently curves interact transmit image center acceptance in any manufalled method to define a QC strategy which maximizes power whilst maintaining acceptable precision, enabling an 29% increase in sample size using str extinct the power of power that the second in the prepare of normalism and the angle is a QC strategy which maximizes power whilst maintaining acceptable precision, enabling an 29% increase in sample size using strictest A 29% increase in sample size using strictest ATS/ERS guidelines in UK Biobank. This identified 15<br>additional genetic loci not found in analysis of UK Biobank using the previous QC criteria, of which 7<br>were not identified in additional genetic loci not found in analysis of UK Biobank using the previous QC criteria, of which 7<br>were not identified in the largest GWAS of lung function to date, and two implicated novel genes<br>highlighting new biolo

additional general differential and the material and the properties and two implicated novel genes highlighting new biology of interest. Eight were already identified in the largest consortium GWAS of lung function to date highlighting new biology of interest. Eight were already identified in the largest consortium GWAS of<br>lung function to date [3], but demonstrate that these discoveries could have been made earlier.<br>In this study, we introd highlighting new biology of the largest and the largest could have been made earlier.<br>In this study, we introduce an iterative selection process to rank acceptability flags in descending<br>order of their impact on spirometer In this study, we introduce an iterative selection process to rank acceptability flags in descervator of their impact on spirometer blow quality failure. We then included blows with variacceptability flags and repeatabilit order of their impact on spirometer blow quality failure. We then included blows with varying<br>acceptability flags and repeatability threshold to refine the spirometry QC criteria for GWAS, with<br>the aim to optimize the sign acceptability flags and repeatability threshold to refine the spirometry QC criteria for GWAS, with<br>the aim to optimize the signal-to-noise ratio. Through the application of this strategy to lung<br>function traits in UK Biob the aim to optimize the signal-to-noise ratio. Through the application of this strategy to lung<br>function traits in UK Biobank, we demonstrated that the statistical power of GWAS can be increased<br>by employing more inclusive function traits in UK Biobank, we demonstrated that the statistical power of GWAS can be increased<br>by employing more inclusive spirometry QC criteria, as evidenced by substantial improvements in<br>sample size, mean chi-squa by employing more inclusive spirometry QC criteria, as evidenced by substantial improvements in<br>sample size, mean chi-square statistics and the identification of additional genetic association<br>signals. These signals implic

by sample size, mean chi-square statistics and the identification of additional genetic association<br>signals. These signals implicated two novel genes for lung function, one of which (*FPR3*) plays a role<br>in innate immunity signals. These signals implicated two novel genes for lung function, one of which (*FPR3*) plays a role<br>in innate immunity and has been implicated in asthma and allergic disease.<br>To date, although 1020 genetics signals hav signals. These signals implicated two novel genes for lung function, one of which (FPR3) plays a role<br>in innate immunity and has been implicated in asthma and allergic disease.<br>To date, although 1020 genetics signals have To date, although 1020 genetics signals have been discovered for lung fur<br>genetic contribution to lung function remains unexplained[3]. The problen<br>could explained by undetected common variant associations and rare<br>approac genetic contribution to lung function remains unexplained[3]. The problem of "missing heritability" could explained by undetected common variant associations and rare variant associations. The approach we outline here will general extintion to lung function to lung function remains the protection remains could explained by undetected common variant associations and rare variant associations. The approach we outline here will boost power for approach we outline here will boost power for GWAS of common/ rare variants such as those now<br>available through the whole genome sequencing of UK Biobank [16], structural genomic variants as<br>long read sequencing data becom available through the whole genome sequencing of UK Biobank [16], structural genomic variants as<br>long read sequencing data become available. While the QC criteria established in UK Biobank may<br>not be directly transferable long read sequencing data become available. While the QC criteria established in UK Biobank may<br>not be directly transferable to other studies, the same methodology can be applied. Our approach<br>will be especially relevant w Final sequencing and become available. The criteria established in the Control of the directly transferable to other studies, the same methodology can be applied. Our approach will be especially relevant where sample sizes not be especially relevant where sample sizes are limited, such as in under-represented ancestries in genomic studies[17]. Furthermore, whilst genetic data are used to inform the spirometry QC, the increase in sample size where sepection, the therm where sample sizes are matters, such a new the increase in sample size and power from our approach is could be applicable to a wide range of epidemiological research questions, such as assessing genomic standard connect general arms and power from our approach is could be applicable to a wide range of epidemiological research questions, such as assessing lung function associations with environmental factors or bio increase in sample size and power from our approach is could be approach is a mini-vinger epidemiological research questions, such as assessing lung function associations with environmental factors or biomarker levels. Bio epidemiological research questions, such as a such as assessing lung functions or biomarker levels. Biomarker measures are becoming more available as biotechnology<br>6 factors or biomarker measures are becoming more available as biotechnology<br> $\overline{6}$ 

requiring intricate QC steps.<br>One limitation of our study is that we were not able to assess all ATS/ERS spirometry QC criteria. To<br>fully meet 2019 ATS/ERS QC criteria, blows must also be free from glottic closure and from requiring intricate QC steps.<br>One limitation of our study if<br>fully meet 2019 ATS/ERS QC<br>of technical issues (faulty ze<br>automated spirometer outp<br>which would be expected to<br>In summary, our study higl fully meet 2019 ATS/ERS QC criteria, blows must also be free from glottic closure and from evidence<br>of technical issues (faulty zero-flow setting, leak or obstruction). These are not generally included in<br>automated spirome

Fully meet 2019 ATS/ERS (faulty zero-flow setting, leak or obstruction). These are not generally included in<br>automated spirometer output. Additionally, the analysis could benefit from a more powerful PRS,<br>which would be ex of technical isotopic technical is understanded spirometer output. Additionally, the analysis could benefit from a more powerful PRS, which would be expected to yield superior prediction performance.<br>In summary, our study and the world be expected to yield superior prediction performance.<br>
In summary, our study highlights a useful application of GRS in epidemiological studies of lung<br>
function. GRS-informed QC boosts sample size and power f In summary, our study highlights a useful application of GRS in function. GRS-informed QC boosts sample size and power for epide<br>by our discovery of new genetic associations for lung function. R sare available from https:/ Function. GRS-informed QC boosts sample size and power for epidemiological studies, as illustrated<br>by our discovery of new genetic associations for lung function. R scripts implementing this analysis<br>are available from <u>h</u> function. GRS-information. GRS-information. GRS-informed QC.<br>by our discovery of new genetic associations for lung function. R scripts implementing this analysis<br>are available from <u>https://github.com/legenepi/GRS informed</u> by the metric cyclin associations for discovery of new stripts informed and scripts implementing this analysis<br>are available from <u>https://github.com/legenepi/GRS\_informed\_QC</u>. are available from https://gitt.up/default.org/<br>are available from the community of the co<br>community of the community of the community of the community of





 $\overline{d}$  ind in the spirogram was greater than 5%.<br>the spirogram was greater than 5%.<br>Panalysis for this study, a repeatability. the spirogram was greater than 5 study, a repeatability of this study, a repeatability of the set of the set of the spirogram of the spir In previous lung function GMAS applied.<br>
In our baseline and in the study, and is a repeated of the st of 250ml was applied.



Table 2: The GRS association with FEV<sub>1</sub>/FVC derived from blows with varying inclusion criteria and repeatability threshold.

or standard dev<br>
EXP<br>
The Second e of FEV<sub>1</sub>/FVC per SD change of GRS<br>Analysis of GRS<br>400 3935 1683545 169.49 393545<br>400 393545 169.49 393545 169.49 393545<br>400 394.49 394.49 394.49 394.49 394.49 394.49 394.49 394.49 394.49 394.49 394.49 394.49 394.49 394. \* stands for standard deviation (SD) change of FEV1/FVC per SD change of GRS



Figure 1: Volume-time curve. The curve plots the total volume of air expired by time, from full inspiration until full expiration. Normal blow shows rapid increase in volume of air expired initiation curve forms a plateau; inspiration until the inputation is that all the increase in the computation. Then curve forms a plateau; Obstructive blow shows prolonged increase but ends the same point;<br>Restrictive blow shows rapid increase as normal, then curve forms a plateau; Obstructive forms a plateau much some point;<br>Restrictive blow shows rapid increase as normal, but curve forms a plateau much sooner. Restrictive blow shows rapid increase as normal, but curve forms a plateau much sooner.



Utilising hundreds to millions of genetic variants to construct weighted GRS/PRS



Figure 2: Basic principle of constructing GRS/PRS. Schematic showing the principles of constructing<br>a GRS. Top section (a) shows a theoretical example of an unweighted risk score is calculated at three<br>SNPs, assuming an ad SNPs, assuming an additive model; middle section (b) shows a weighted risk score for the same<br>alleles, whereby the score for each allele is weighted according to its association with lung function;<br>bottom section (c) shows alleles, whereby the score for each allele is weighted according to its association with lung funct<br>bottom section (c) shows a normal distribution of individual scores for a GRS/PRS using hundrec<br>millions of genetic varian bottom section (c) shows a normal distribution of individual scores for a GRS/PRS using hundreds to<br>millions of genetic variants, where the score at each variant is weighted according to its association<br>with the trait of i bottom section (c) shows a normal distribution of the state of individual scores in the section of genetic variants, where the score at each variant is weighted according to its association with the trait of interest (lung millions of generations, with the trait of interest (lung function), ideally in an independent population. with the trait of interest (lung function), ideally in an independent population.



rigure 3: Flowchart for evaluating spirometer blow quality and spirometry QC criteria. Definitions<br>of acceptability flags ("COUGH", "EXPFLOW", "END", "START", "START2", "CONSISTENCY",<br>"NEGATIVE", "REJECT") were given in Ta "NEGATIVE", "REJECT") were given in Table 1.<br>"NEGATIVE", "REJECT") were given in Table 1. WEGATIVE", "REJECT") were given in Table 1.



FEV<sub>1</sub>/FVC derived from spirometer blows stratified by acceptability flags shown as the s.d. change in FEV<sub>1</sub>/FVC per s.d. increase in GRS. N.B. A blow could be included in multiple acceptability flag strata if it carries FEV<sub>1</sub>/FVC per s.d. increase in GRS. N.B. A blow could be included in multiple acceptability flag strata<br>if it carries multiple acceptability flags. **b**, Iterative selection process. **c**, GRS association with<br>FEV<sub>1</sub>/FVC de If it carries multiple acceptability flags. **b**, Iterative selection process. **c**, GRS association with FEV<sub>1</sub>/FVC derived from grouped spirometer blows shown as the s.d. change in FEV<sub>1</sub>/FVC per s.d. increase in GRS. Gro if it carries multiple acceptability flags. **b**, Iterative selection process. **c**, GRS association with FEV<sub>1</sub>/FVC derived from grouped spirometer blows shown as the s.d. change in FEV<sub>1</sub>/FVC per s.d. increase in GRS. Grou FEVI/FITE INTERT IS COMPLIF PRESENT INTERTATION INTERTATION INTERTS IN THE SERVIES IN GRIS. Group 1 represents blows with hesitation flags only ("START" or "START2"). Group 2 represents blows with cough, end-of-blow or tim increase in Group 1 represents blows with cough, end-of-blow or time to peak flow flags ("COUGH", "END" or "RESPFLOW") but without flags of "REJECT", "CONSISTENCY" or "NEGATIVE". Group 3 represents blows with acceptability "EXPFLOW") but without flags of "REJECT", "CONSISTENCY" or "NEGATIVE". Group 3 represents<br>blows with acceptability flags of "REJECT", "CONSISTENCY" or "NEGATIVE". The height of the bars<br>shows the point estimate of the effe blows with acceptability flags of "REJECT", "CONSISTENCY" or "NEGATIVE". The height of the bars<br>shows the point estimate of the effect and whiskers show the 95% Cl.<br>Shows the point estimate of the effect and whiskers show blows the point estimate of the effect and whiskers show the 95% CI.<br>
Shows the point estimate of the effect and whiskers show the 95% CI. shows the point estimate of the effect and whiskers show the 95% CI.



Figure 5: Examine the genetic association results of FEV<sub>1</sub>/FVC signals estimated from relaxed blow<br>inclusive criteria at varying repeatability threshold of 250 ml, 300 ml and 350 ml. a, compare the inclusive criteria at varying repeatability direshold of 250 ml, 500 ml and 350 ml. a, compare the<br>effect sizes of FEV<sub>1</sub>/FVC signals using relaxed spirometry QC (New effect size, including blows<br>previously only excluded f previously only excluded for cough, hesitation, excessive time to peak flow or lack of terminal<br>plateau ("START", "START2", "COUGH", "END", "EXPFLOW") in addition to accepted blows) to<br>result obtained from previous spirome plateau ("START", "START2", "COUGH", "END", "EXPFLOW") in addition to accepted blows) to<br>result obtained from previous spirometry QC (Previous effect size, only including accepted blo<br>compare the p values of FEV<sub>1</sub>/FVC sig positive that independent obtained from previous spirometry QC (Previous effect size, only including accepted blows).<br>compare the p values of FEV<sub>1</sub>/FVC signals using relaxed spirometry QC (New -log(P)) to the result<br>obta result obtained from previous spirometry QC (Frevious effect size, only including accepted blows). b,<br>compare the p values of FEV<sub>1</sub>/FVC signals using relaxed spirometry QC (New -log(P)) to the result<br>obtained from previou obtained from previous spirometry QC (Previous -log(P)) to the results of  $\alpha$ obtained from previous spirometry QC (Previous -log(P)).

- 1. Youn<br> *lung*<br>
p. 61<br>
2. Vissc<br>
Amer<br>
3. Shrin<br> *gene*
- 
- 1. Young, R.P., R. Hopkins, and T.E. Eaton, Forced expiratory volume in one second: not just a<br>lung function test but a marker of premature death from all causes. Eur Respir J, 2007. 30(4<br>p. 616-22.<br>2. Visscher, P.M., et a rang function test but a marker of premature death from an causes. Eur Respir 3, 2007. 30(4).<br>p. 616-22.<br>Visscher, P.M., et al., 10 Years of GWAS Discovery: Biology, Function, and Translation. The<br>American Journal of Human *Fisscher, P*<br>Visscher, P<br>American J<br>Shrine, N.,<br>*genes and<br>risk.* Natur<sub>i</sub><br>S1(3): p. 48 2. Vissencr, P.M., et al., 10 Years of GWAS Discovery: Biology, Panction, and Translation. The<br>American Journal of Human Genetics, 2017. 101(1): p. 5-22.<br>3. Shrine, N., et al., *Multi-ancestry genome-wide association analy* American Journal of Human Genetics, 2017. 101(1): p. 5-22.<br>Shrine, N., et al., *Multi-ancestry genome-wide association an*<br>genes and pathways influencing lung function and chronic of<br>risk. Nature Genetics, 2023. 55(3): p. genes and pathways influencing lung function and chronic obstructive pulmonary disease<br>risk. Nature Genetics, 2023. **55**(3): p. 410-422.
- 3. Shrine, N., et al., *Multi-ancestry genome-wide association analyses improve resolution of*<br>genes and pathways influencing lung function and chronic obstructive pulmonary disease<br>risk. Nature Genetics, 2023. 55(3): p. 4 risk. Nature Genetics, 2023. **33**(3): p. 410-422.<br>Shrine, N., et al., *New genetic signals for lung f*<br>obstructive pulmonary disease associations acr<br>**51**(3): p. 481-493.<br>Graham, B.L., *Pulmonary function standards: a*<br>119
- 
- 4. Shrine, N., et al., New genetic signals for lang function miginight pathways and chronic<br>
obstructive pulmonary disease associations across multiple ancestries. Nat Genet, 2015<br>
51(3): p. 481-493.<br>
Graham, B.L., Pulmona obstructive pulmonary alsease associations across multiple ancestries. Nat Genet, 2015.<br>51(3): p. 481-493.<br>Graham, B.L., *Pulmonary function standards: a work in progress.* Respir Care, 2012. 57(7<br>1199-200.<br>Haynes, J.M. an **S1(3): p. 481-493.**<br>Graham, B.L., *Puln*<br>1199-200.<br>Haynes, J.M. and E<br>*Society Acceptabili*<br>Care, 2015. **60(5):**<br>Hankinson, J.L., et<br>*quality criteria for*<br>Choi, S.W., T.S. Ma 5. Graham, B.L., Palmonary Janction standards: a work in progress. Respir care, 2012. 57(7): p.<br>
1199-200.<br>
Haynes, J.M. and D.A. Kaminsky, The American Thoracic Society/European Respiratory<br>
Society Acceptability Criteria ----<br>Haynes, J.M<br>*Society Acc*<br>Care, 2015<br>Hankinson<br>*quality crit*<br>Choi, S.W.,<br>*analyses*. N<br>Sudlow, C.<sub>,</sub> 6. Haynes, J.M. and D.A. Kaminisky, The American Thoracic Society/European Respiratory<br>
Society Acceptability Criteria for Spirometry: Asking Too Much or Not Enough? Respirat<br>
Care, 2015. 60(5): p. e113-e114.<br>
Hankinson, J
- Society Acceptability Criteria for Spirometry: Asking Too Midel or Not Enough? Respiratory<br>Care, 2015. 60(5): p. e113-e114.<br>Hankinson, J.L., et al., Use of forced vital capacity and forced expiratory volume in 1 second<br>qua Care, 2015. **00**(5): p. e113-e114.<br>Hankinson, J.L., et al., *Use of forc*<br>*quality criteria for determining a*<br>Choi, S.W., T.S. Mak, and P.F. O'F<br>*analyses.* Nat Protoc, 2020. **15**(9)<br>Sudlow, C., et al., *UK biobank: an*<br>r
- 
- 7. Hankinson, J.L., et al., Ose of foreed vital capacity and forced expiratory volume in 1 second<br>quality criteria for determining a valid test. Eur Respir J, 2015. 45(5): p. 1283-92.<br>8. Choi, S.W., T.S. Mak, and P.F. O'Re quality criteria for determining a valid test. Eur Respir 3, 2013. 43(3): p. 1203-92.<br>Choi, S.W., T.S. Mak, and P.F. O'Reilly, *Tutorial: a guide to performing polygenic r*<br>analyses. Nat Protoc, 2020. **15**(9): p. 2759-2772 8. Choi, S.W., T.S. Mak, and P.F. O'Reilly, Tutorial: a guide to performing polygenic risk score<br>analyses. Nat Protoc, 2020. **15**(9): p. 2759-2772.<br>9. Sudlow, C., et al., *UK biobank: an open access resource for identifyin*
- 
- 
- analyses. Nat Protoc, 2020. 13(9): p. 2759-2772.<br>Sudlow, C., et al., *UK biobank: an open access res*<br>range of complex diseases of middle and old age.<br>Miller, M.R., et al., *Standardisation of spirometry*<br>p. 319-338.<br>Loh, 9. Sudlow, C., et al., *C. Biobank: an open access resource for identifying the causes of a wide*<br>
range of complex diseases of middle and old age. PLoS Med, 2015. 12(3): p. e1001779.<br>
10. Miller, M.R., et al., *Standardis* range of complex diseases of middle and old age. PLOS Med, 2013. 12(3): p. e1001773.<br>Miller, M.R., et al., *Standardisation of spirometry.* European Respiratory Journal, 2005.<br>p. 319-338.<br>Loh, P.-R., et al., *Efficient Bay* 10. Miller, M.R., et al., *standardisation of spirometry.* European Respiratory Journal, 2003. 20(2):<br>
11. Loh, P.-R., et al., *Efficient Bayesian mixed-model analysis increases association power in large*<br>
cohorts. Nature P. - B. - Cohorts.<br>Loh, P.-R., e<br>*cohorts.* Nat<br>Okbay, A., e<br>symptoms, e<br>**48**(6): p. 624<br>Turley, P., e<br>MTAG. Natu<br>Alexander, I 11. Evin, P. R., et al., Efficient Bayesian mixed model analysis increases association power in large<br>
cohorts. Nature Genetics, 2015. 47(3): p. 284-290.<br>
12. Okbay, A., et al., Genetic variants associated with subjective conorts. Nature Genetics, 2013. 47(3): p. 264-250.<br>Okbay, A., et al., *Genetic variants associated with s*<br>symptoms, and neuroticism identified through gene<br>**48**(6): p. 624-33.<br>Turley, P., et al., *Multi-trait analysis of* 12. Okbay, A., et al., Genetic variants associated with subjective well-being, depressive<br>symptoms, and neuroticism identified through genome-wide analyses. Nat Genet, 2<br>48(6): p. 624-33.<br>13. Turley, P., et al., Multi-trai
- 
- 
- symptoms, and neuroticism identified through genome wide analyses. Nat Genet, 2016.<br>48(6): p. 624-33.<br>Turley, P., et al., *Multi-trait analysis of genome-wide association summary statistics usin*<br>MTAG. Nature Genetics, 201 48(6): p. 624-33.<br>Turley, P., et al., *I*<br>*MTAG.* Nature Ge<br>Alexander, D.H., .<br>*unrelated individ*<br>Dorward, D.A., et<br>governing neutro<br>1172-84.<br>Li, S., et al., *Whol* 13. Turley, P., et al., Multi-trait analysis of genome-wide association summary statistics using<br>
MTAG. Nature Genetics, 2018. 50(2): p. 229-237.<br>
14. Alexander, D.H., J. Novembre, and K. Lange, *Fast model-based estimatio* MTAG. Nature Genetics, 2018. **30**(2): p. 223-237.<br>Alexander, D.H., J. Novembre, and K. Lange, *Fast i*<br>unrelated individuals. Genome Res, 2009. **19**(9): p<br>Dorward, D.A., et al., *The role of formylated pepti*<br>governing neu 14. Alexander, D.H., J. Novembre, and K. Lange, Past moder based estimation by antestry in<br>
15. Dorward, D.A., et al., The role of formylated peptides and formyl peptide receptor 1 in<br>
15. Dorward, D.A., et al., The role o unrelated malviduals. Genome Res, 2009. 19(9): p. 1033-64.<br>Dorward, D.A., et al., *The role of formylated peptides and for*<br>governing neutrophil function during acute inflammation. An<br>1172-84.<br>Li, S., et al., *Whole-genome* 15. Borward, D.A., et al., *The role of formylated peptides and formyr peptide receptor 1 in*<br>governing neutrophil function during acute inflammation. Am J Pathol, 2015. **185**(5): p<br>1172-84.<br>Li, S., et al., *Whole-genome s*
- governing neutrophil function during acute inflammation. Am J Pathol, 2015. 185(5): p.<br>1172-84.<br>Li, S., et al., Whole-genome sequencing of half-a-million UK Biobank participants. medR:<br>2023: p. 2023.12.06.23299426.<br>Fatumo, Li, S., et a<br>2023: p. 2<br>Fatumo, S<br>p. 243-25
- 16. Li, S., et al., Whole-genome sequencing of half-a-million of Biobank participants. meditary,<br>2023: p. 2023.12.06.23299426.<br>17. Fatumo, S., et al., *A roadmap to increase diversity in genomic studies*. Nat Med, 2022. **2** Fatumo, S., et al., *A roadmap to*<br>p. 243-250.<br>. 17. Fatumo, S., et al., A roadmap to increase diversity in genomic studies. Nat Med, 2022. 28(2):<br>p. 243-250. p. 243-250.

Supplementary Data for the manuscript entitled "Genetic risk score-informed re-evaluation of spirometry quality control to maximise power in epidemiological studies of lung function".

# Table of Contents



# Supplementary Methods

### Constructing GRS and testing its association with lung function traits

215, 372 and 442 autosomal signals (genome-wide significant threshold of  $P < 5 \times 10^{-9}$ ) associated<br>with each trait respectively, using weights estimated from a multi-ancestry meta-regression in<br>244,472 individuals across 425, 372 and 442 autosomal signals (genome-wide significant threshold of  $P < 5 \times 10^{-9}$ ) associated<br>with each trait respectively, using weights estimated from a multi-ancestry meta-regression in<br>244,472 individuals across 244,472 individuals across 42 cohorts (**Supplementary Table 1**) that are independent from the UK<br>Biobank[3]. We calculated the GRSs for 406,474 European-ancestry individuals in UK Biobank The<br>associations between GRSs and

 $244,472$  individuals across 42 conorts (**Supplementary Table 1**) that are independent from the OK<br>Biobank[3]. We calculated the GRSs for 406,474 European-ancestry individuals in UK Biobank The<br>associations between GRSs a associations between GRSs and lung function traits were tested using a linear model, adjusted for<br>age, age squared, sex, height, smoking status and ten principal components.<br>For the first step of GRS association with lung age, age squared, sex, height, smoking status and ten principal components.<br>
For the first step of GRS association with lung function traits stratified all the blows by acceptability<br>
flag, a blow could be included in mult For the first step of GRS association with lung function traits stratified all th<br>flag, a blow could be included in multiple strata if it had multiple accepta<br>acceptability flag stratum, we identified the best lung functi For the first step of GRS association with lung function training and the first strategies. Within each acceptability flag stratum, we identified the best lung function measures (i.e. the best measure was defined as the h acceptability flag stratum, we identified the best lung function measures (i.e. the best measure was defined as the highest measure for FEV<sub>1</sub> and FVC, whilst FEV<sub>1</sub>/FVC was derived from the selected FEV<sub>1</sub> and FVC) for e defined as the highest measure for FEV<sub>1</sub> and FVC, whilst FEV<sub>1</sub>/FVC was derived from the selected<br>FEV<sub>1</sub> and FVC) for each participant and tested the association of the GRS with the measured lung<br>function trait to identi

#### Bayesian framework to assess the credibility of GWAS findings

defined as the highest measure for FEV<sub>1</sub> and FFEV<sub>1</sub> and FVC) for each participant and tested the association of the GRS with the measured lung function trait to identify which strata were significantly associated with t Function trait to identify which strata were significantly associated with the GRS.<br>Bayesian framework to assess the credibility of GWAS findings<br>For genome-wide association testing under an additive model using BOLT-LMM[ Function training interaction testing under an additive model using BOLT-<br>For genome-wide association testing under an additive model using BOLT-<br>untransformed residuals from linear regression of lung function traits agai For genome-wide association testing and the contrast of lung function traits against age, age<sup>2</sup>, sex, height,<br>smoking status. To assess the credibility of our findings from the genetic association study using the<br>relaxed relaxed spirometry QC criteria, we used a standard Bayesian framework previously described by<br>Okbay *et al*[12] and Turley *et al*[13]. Briefly, we used maximum likelihood to fit the SNP effect from<br>the GWAS result using Okbay *et al*[12] and Turley *et al*[13]. Briefly, we used maximum likelihood to fit the SNP effect from<br>the GWAS result using a mixture of a Gaussian prior with a point mass at zero. The prior for effect<br>size correspondi Okbay et al<sub>1</sub>12] and Turley et al<sub>1</sub>13]. Briefly, we used maximum likelihood to it the SNP effect rom<br>the GWAS result using a mixture of a Gaussian prior with a point mass at zero. The prior for effect<br>size corresponding

$$
\beta_j \sim \begin{cases} N(0, \tau^2) & \text{with probability } \pi \\ 0 & \text{otherwise} \end{cases}
$$

the CONTREST and SUP is<br>size corresponding to any given SNP j is<br> $\beta_j \sim \begin{cases} N(0, \tau^2) & with \ probability \pi \ 0 & otherwise \end{cases}$ <br>where  $\tau^2$  is the prior belief of the variance of effect size of non-null SNPs and  $\pi$  is the prior belief of<br>the f  $\beta_j \sim \begin{cases} N(\beta) \end{cases}$ <br>where  $\tau^2$  is the prior belief of the variation of non-null SNPs. For each<br>likelihood estimates of parameters to cats<br>its estimated effect size and given that 。<br>。<br>. where  $\tau^2$ <br>the fracti<br>likelihood<br>its estima<br>independ is the prior belief of the variance of effect size of non-null SNPs and *h* is the prior belief of<br>on of non-null SNPs. For each assumed prior  $\pi$  from 1% to 99%, we used the maximum<br>lestimates of parameters to calculate the fraction of non-null SNPs. For each assumed prior *h* from 1% to 99%, we used the maximum<br>likelihood estimates of parameters to calculate the posterior probability that a SNP is non-null given<br>its estimated effect siz its estimated effect size and given that it is significant. To assess the replication of the effect size in<br>independent study, the effect size for each SNP is corrected for winner's curse by<br> $\hat{\beta}_{adj,j} = (1 - \pi_{posterior,j}) \frac{\hat{\tau}^2}{$ 

$$
\hat{\beta}_{adj,j} = (1 - \pi_{posterior,j}) \frac{\hat{\tau}^2}{\hat{\tau}^2 + \hat{\sigma}_j^2} \hat{\beta}_j
$$

independent study, the effect size for each SNP is corrected for winner's curse by<br>  $\hat{\beta}_{adj,j} = (1 - \pi_{posterior,j}) \frac{\hat{\tau}^2}{\hat{\tau}^2 + \hat{\sigma}_j^2} \hat{\beta}_j$ <br>
where  $\pi_{posterior,j}$  is the posterior probability of the SNP *j* being non-null and  $\$  $\hat{\beta}_{adj,j} = (1 - \pi_{posterior,j}) \frac{\hat{\tau}^2}{\hat{\tau}^2 + \hat{\sigma}_j^2} \hat{\beta}_j$ <br>where  $\pi_{posterior,j}$  is the posterior probability of the SNP  $j$  being non-null and<br>standard error of the GWAS estimates for SNP  $j$ .  $\beta$ <br>where  $\pi_{posterior,j}$  is the<br>standard error of the GW,  $\frac{1}{2}$ where  $n_{post}$ <br>standard erro  $\eta_{\text{prior},j}$  is the posterior probability of the SNP j being non-null and  $o_j$ <br>in of the GWAS estimates for SNP j. is the squared standard error of the GWAS estimates for SNP j.

# Supplementary Figures



Supplementary Figure 1: Ranking the impact of acceptability flags on spirometer blows. **a,** GRS association with FEV<sub>1</sub> derived from spirometer blows stratified by<br>acceptability flags shown as the s.d. change in FEV<sub>1</sub> per s.d. increase in GRS. N.B. A blow could be<br>included in multiple acc acceptability flags stranged in multiple acceptability flags stranged in multiple acceptability flags. **b**, Iterative selection process. **c**, GRS association with FEV<sub>1</sub> derived from grouped spirometer blows shown as the included in multiple acceptability ring strata in it carries multiple acceptability rings. b, iterative<br>selection process. c, GRS association with FEV<sub>1</sub> derived from grouped spirometer blows shown as<br>the s.d. change in FE selection process. c, GRS association with FEV1 derived from grouped spirometer blows shown as<br>the s.d. change in FEV<sub>1</sub> per s.d. increase in GRS. Group 1 represents blows with hesitation flags only<br>("START" or "START2"). ("START" or "START2"). Group 2 represents blows with cough, end-of-blow or time to peak flow flags<br>("COUGH", "END" or "EXPFLOW") but without flags of "REJECT", "CONSISTENCY" or "NEGATIVE".<br>Group 3 represents blows with acc ("COUGH", "END" or "EXPFLOW") but without flags of "REJECT", "CONSISTENCY" or "NEGATIVE".<br>Group 3 represents blows with acceptability flags of "REJECT", "CONSISTENCY" or "NEGATIVE". The<br>height of the bars shows the point e ("COUGH") and the United Handle Hags of "REJECT", "CONSISTENCY" or "NEGATIVE". The<br>Group 3 represents blows with acceptability flags of "REJECT", "CONSISTENCY" or "NEGATIVE". The<br>height of the bars shows the point estimate Group 3 represents blows the point estimate of the effect and whiskers show the 95% Cl<br>height of the bars shows the point estimate of the effect and whiskers show the 95% Cl height of the bars shows the point estimate of the effect and whiskers show the 95% CI



 Supplementary Figure 2: Ranking the impact of acceptability flags on spirometer blows. **a**, GRS association with FVC derived from spirometer blows stratified by acceptability flags shown as the s.d. change in FVC per s.d. increase in GRS. N.B. A blow could be included in multiple acceptabil included in multiple acceptability flag strata if it carries multiple acceptability flags. **b**, Iterative selection process. **c**, GRS association with FVC derived from grouped spirometer blows shown as the s.d. change in F included in multiple acceptability ring strata in it carries multiple acceptability rings. b, iterative<br>selection process. c, GRS association with FVC derived from grouped spirometer blows shown as<br>the s.d. change in FVC p selection process. c, GRS association with FVC derived from grouped spirometer blows shown as<br>the s.d. change in FVC per s.d. increase in GRS. Group 1 represents blows with hesitation flags only<br>("START" or "START2"). Grou ("START" or "START2"). Group 2 represents blows with cough, end-of-blow or time to peak flow flags<br>("COUGH", "END" or "EXPFLOW") but without flags of "REJECT", "CONSISTENCY" or "NEGATIVE".<br>Group 3 represents blows with acc ("COUGH", "END" or "EXPFLOW") but without flags of "REJECT", "CONSISTENCY" or "NEGATIVE".<br>Group 3 represents blows with acceptability flags of "REJECT", "CONSISTENCY" or "NEGATIVE". The<br>height of the bars shows the point e ("COUGH") and the United Handle Hags of "REJECT", "CONSISTENCY" or "NEGATIVE". The<br>Group 3 represents blows with acceptability flags of "REJECT", "CONSISTENCY" or "NEGATIVE". The<br>height of the bars shows the point estimate Group 3 represents blows the point estimate of the effect and whiskers show the 95% Cl<br>height of the bars shows the point estimate of the effect and whiskers show the 95% Cl height of the bars shows the point estimate of the effect and whiskers show the effect and whiskers show the 9<br>Similar shows the 95% City of the 95% City of the 95% City of the 95% City of the 95% City<br>Similar show the 95%

# Supplementary Tables

Supplementary Table 1: Sample size in 42 non-UKB cohorts





### Supplementary Table 2: Additional signals for FEV<sub>1</sub>/FVC using relaxed spirometry QC criteria

\*It was defined as novel if the sentinel SNP was not within 1 MB distance to the sentinels reported in Shrine et al. 2023 or if the sentinel SNP was not in LD with the sentinels reported in Shrine et al. 2023  $(R^2<0.2)$ 

\*\*This column indicates whether the nearest gene of the sentinel SNP was reported either in Shrine et al. 2023 or other studies in GWAS Catalog